Contrasting BioNexus Gene Lab (NASDAQ:BGLC) & PACS Group (NYSE:PACS)

BioNexus Gene Lab (NASDAQ:BGLC) and PACS Group (NYSE:PACS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Valuation and Earnings

This table compares BioNexus Gene Lab and PACS Group”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$9.51 million	0.98	-$1.60 million	N/A	N/A
PACS Group	$3.11 billion	0.62	$112.87 million	N/A	N/A

PACS Group has higher revenue and earnings than BioNexus Gene Lab.

Volatility and Risk

BioNexus Gene Lab has a beta of 5.2, suggesting that its stock price is 420% more volatile than the S&P 500. Comparatively, PACS Group has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for BioNexus Gene Lab and PACS Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	1	0	0	0	1.00
PACS Group	1	1	3	0	2.40

PACS Group has a consensus target price of $26.25, suggesting a potential upside of 106.04%. Given PACS Group’s stronger consensus rating and higher probable upside, analysts plainly believe PACS Group is more favorable than BioNexus Gene Lab.

Insider & Institutional Ownership

18.9% of BioNexus Gene Lab shares are held by institutional investors. 0.7% of BioNexus Gene Lab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares BioNexus Gene Lab and PACS Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-30.70%	-35.54%	-29.08%
PACS Group	N/A	N/A	N/A

Summary

PACS Group beats BioNexus Gene Lab on 8 of the 12 factors compared between the two stocks.

About BioNexus Gene Lab

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

About PACS Group

PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.